Welcome to our dedicated page for NRX Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. reports clinical, regulatory, manufacturing, and subsidiary developments for a biopharmaceutical business focused on neuroplastic therapies for depression, PTSD, suicidality, and related conditions. Company updates center on NRX-100 preservative-free ketamine, NRX-101 as a D-cycloserine/lurasidone fixed-dose combination, FDA communications, generic-drug and new-drug application pathways, and clinical work involving treatment-resistant depression and suicidality.
Recurring news also covers commercial manufacturing preparations, drug-shortage context for ketamine injection, robotic-enabled transcranial magnetic stimulation initiatives through NRx Defense Systems, and interventional psychiatry activity through HOPE Therapeutics. Additional company developments include partnerships involving digital monitoring tools, leadership appointments, and research programs serving military, first-responder, and broader behavioral-health settings.
NRx Pharmaceuticals (NRXP) reports that the FDA has reclassified an amendment to its Abbreviated New Drug Application for preservative-free ketamine from a Major Amendment to a Minor Amendment, and has revised the Generic Drugs User Fee Act (GDUFA) goal date to November 10, 2026.
The FDA communication, from the Director of Regulatory Operations of the Office of Generic Drugs, states that the reclassified amendment will not require a substantial expenditure of FDA resources. The company characterizes this product as a strategic drug intended to address a drug shortage. NRx is developing NRX-100 (preservative-free intravenous ketamine) for suicidal ideation in depression, including bipolar depression, and NRX-101 (oral D-cycloserine/lurasidone) for suicidal bipolar depression, both of which have received expedited FDA designations.
GeNeuro, Inc., an NRx company (NRXP) received a European patent (EP 3 570 878 B1) for GNK-301, a monoclonal antibody drug candidate targeting Amyotrophic Lateral Sclerosis (ALS).
The patent, co-owned with the US Dept. of Health and Human Services, covers an anti‑HERV K Envelope antibody that has blocked K Env–induced neurotoxicity in laboratory animals and human motor neuron cells. It complements two previously granted US patents (10,723,787 and 10,981,977) and expands a portfolio of more than 25 issued and pending HERV-related patents. GeNeuro has initiated cGMP manufacture of GNK-301 and plans human Phase 1 trials in ALS in the US and Europe. A related antibody, Temelimab, has already been tested in five trials in more than 400 participants, showing statistically significant reductions in neurodegeneration on MRI and no Serious Adverse Events.
NRx Pharmaceuticals (NRXP) announced that subsidiary HOPE Therapeutics is deploying Zeta Surgical's newly FDA-cleared robotic TMS system in Florida clinics. HOPE is the first Interventional Psychiatry network to use the Zeta TMS Robotic System, with its clinical team completing orientation and training at Zeta Surgical's Boston headquarters ahead of deployment. The AI-driven platform adjusts the TMS coil in real time with submillimeter precision, extending the Zeta TMS Navigation System HOPE began using in June 2026. The rollout supports SPARC-TMS, NRx's FDA-approved Phase 2/3 trial of NRX-101 combined with robotic TMS, planned across an academic hospital, multiple HOPE clinics, and two military treatment facilities, with NRx selected by DARPA as prime contractor subject to contracting. NRx is also participating in a fireside chat at the 2026 Cantor Global Healthcare Conference, with a live webcast available on its investor relations website.
NRx Pharmaceuticals (NRXP) will present at three investor conferences in New York in September 2026, featuring Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H. Presentations include a company talk at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9, a fireside chat at the 2026 Cantor Global Healthcare Conference on September 11, and a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, with times ranging from morning to mid-afternoon Eastern Time.
Live webcasts and replays will be available via the Events page in the Investors section of the NRx Pharmaceuticals website.
NRx Pharmaceuticals (Nasdaq: NRXP) reported second quarter 2026 results and a corporate update, highlighting progress on preservative-free ketamine, NRX-101, and its NMDA-based CNS pipeline. The FDA completed first-cycle review of the ANDA for preservative-free ketamine with no drug-related major deficiencies; a requested manufacturer attestation on the vial has been submitted, and commercial-scale manufacturing has begun, targeting 5 million launch doses and ongoing production of 1 million units per month with an approval and commercialization goal in 2026.
According to the company, it is advancing an NDA for NRX-100 for depression using Real World Evidence from more than 65,000 patients, aiming for 2027 approval. NRx was selected by DARPA as prime contractor for the SPARC-TMS Phase 2/3 trial of NRX-101 with robotic TMS, with anticipated non-dilutive funding exceeding $11.5 million, subject to contracting. The company also backed the formation of Geneuro, Inc. with two clinical-stage monoclonal antibodies.
For the six months ended June 30, 2026, NRx reported a net loss of $18.0 million versus $23.1 million a year earlier, and an operating loss of $11.3 million versus $7.6 million. Cash and equivalents were $26.7 million at June 30, 2026, up from $7.8 million at December 31, 2025, primarily from a public offering of common stock that raised gross proceeds of about $22.3 million. Management believes current cash, anticipated clinic revenue and its at-the-market facility will fund operations for at least one year.
NRx Pharmaceuticals (Nasdaq: NRXP) will host a conference call and Q&A on Monday, August 10, 2026 at 8:30 a.m. ET to discuss the FDA’s completion of first-cycle review of its ANDA for preservative-free ketamine. CEO Jonathan Javitt, Chief Commercial Officer Glenn Tyson, and Director Chaim Hurvitz will participate. Investors can join via live webcast on the company’s investor relations site or by domestic and international dial-in, with a replay available. NRx is a clinical-stage biopharmaceutical company developing NRX-100 (preservative-free IV ketamine) and NRX-101, both holding FDA Fast Track or Breakthrough Therapy designations for suicidal depression.
NRx Pharmaceuticals (Nasdaq: NRXP) reported that the FDA has completed first-cycle review of its ANDA for preservative-free intravenous ketamine with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC, or other drug-related review matters, and is not requiring new clinical, safety, or efficacy data.
The only remaining item is a packaging-related Major Deficiency: FDA requested manufacturer certification that the luer lock vial tip, already used in three approved ANDA products with 11.9 million complaint-free doses shipped in 12 months, is produced on the same lines and methods. NRx is submitting this attestation, and FDA committed to review it in the shortest possible cycle. NRx views this first-cycle outcome, achieved in a context where only 14–18% of ANDAs are typically approved in first cycle, as a key milestone that de-risks its path to potential approval and commercialization. The company will host a webcast on August 10, 2026 to discuss the update.
Summary not available.
NRx Pharmaceuticals (Nasdaq: NRXP) reported that subsidiary HOPE Therapeutics has treated its first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, Florida.
The AI-guided, sub-millimetric navigation is integrated into outpatient TMS workflows and supports NRx's planned SPARC-TMS trial of NRX-101 with robotic-enabled TMS for depression and suicidality.
Summary not available.